Agenus AGEN
$
Relative Strength Index (RSI)
- The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.
- The RSI is calculated using the following formula:
RSI = 100 - (100 / (1 + RS))
Where RS is the ratio of the average gains to the average losses over a specified period.
- The default time period used is 14 days.
- RSI values range between 0 and 100.
RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)
RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)
RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.
About
Business overview of Agenus (AGEN)
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).
Key Insights
Critical company metrics and information
Latest Closing Price
$2.35Market Cap
$55.49 MillionPrice-Earnings Ratio
1.12Total Outstanding Shares
23.46 Million SharesTotal Employees
389Dividend
No dividendIPO Date
February 4, 2000SIC Description
Biological Products, (no Disgnostic Substances)Primary Exchange
NASDAQType
Common StockHeadquarters
3 forbes road, Lexington, MA, 02421Homepage
https://www.agenusbio.com
Historical Stock Splits
If you bought 120 shares of AGEN before October 3, 2011, you'd have 1 share today.
| Execution Date | Split Amount |
|---|---|
| April 12, 2024 | 1-for-20 (Reverse Split) |
| October 3, 2011 | 1-for-6 (Reverse Split) |
Cash Flow Statement
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Net Cash Flow From Operating Activities | $-170.06 Million |
| Net Cash Flow | $-61.41 Million |
| Net Cash Flow, Continuing | $-61.41 Million |
| Net Cash Flow From Investing Activities, Continuing | $2.87 Million |
| Net Cash Flow From Financing Activities, Continuing | $105.78 Million |
| Net Cash Flow From Operating Activities, Continuing | $-170.06 Million |
Income Statement
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Research and Development | $188.48 Million |
| Basic Earnings Per Share | $2.09 |
| Operating Expenses | $258.58 Million |
| Net Income/Loss Attributable To Parent | $-231.03 Million |
| Net Income/Loss | $-234.05 Million |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0 |
Comprehensive Income
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Other Comprehensive Income/Loss | $-319,000 |
Balance Sheet
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Accounts Payable | $45.90 Million |
| Liabilities And Equity | $238.48 Million |
| Other Current Liabilities | $224.75 Million |
| Current Liabilities | $270.64 Million |
| Other Current Assets | $3.00 Million |
| Noncurrent Liabilities | $239.64 Million |
Historical Dividends
| Announcement Date | Payment Date | Record Date | Amount | Frequency |
|---|---|---|---|---|
| No historical dividends | ||||
Recent Headlines From The Web
Latest news, press releases, and media coverage about AGEN from trusted financial sources
ⓒ 2025 Financhle. All Rights Reserved.